Navigation Links
Inhibiting prostate cancer without disturbing regular body processes
Date:8/9/2010

This release is available in French.

Inhibiting prostate cancer without disturbing regular body processes Researchers explain how a facultative enzyme governs tumour growth

A kinase is a type of enzyme the body uses to regulate the functions of the proteins required for cell growth and maintenance, and researchers have discovered that one in particular plays a key role in developing prostate cancer. "It's known as Mnk, and although it appears not to be essential for normal cell maintenance, it's important for cancer growth" said Dr. Luc Furic, a postdoctoral researcher working with Dr. Nahum Sonenberg at McGill University's Goodman Cancer Research Centre and Department of Biochemistry.

This is a very significant finding because the body's chemical processes are highly complex and interrelated, meaning that targeting one cause of cancer often involves affecting the body's normal functions. An important part of cancer research is about trying to find processes that can be inhibited or stopped without causing damages to normal tissue.

The chemical process Mnk uses is known as phosphorylation, and this process activates or inactivates the body's proteins, controlling mechanisms that can cause disease. In this case, Mnk works with a protein known as eIF4E to synthesize proteins in the cell.

Researchers at the Centre hospitalier de l'Universit de Montral Research Centre (CRCHUM), Universit de Montral and McGill University engineered mice that were able to block the phosphorylation process of this protein, and discovered that these mice became resistant to prostate cancer growth. "The PTEN gene and its protein act as a tumour suppressor," explained Dr. Fred Saad, researcher at the CRCHUM and at Universit de Montral's Department of Surgery. "By removing this gene in the mouse prostate, we were able to study eIF4E's effect on cell growth."

The research is directly related to humans, because PTEN is frequently mutated in human prostate cancer. Studies on cancer patients have confirmed eIF4E's involvement.

The task ahead will be to find a specific and selective pharmacological inhibitor of Mnks. Although some inhibitors are used for research purposes, these inhibitors are not highly specific to this kinase.


'/>"/>

Contact: William Raillant-Clark
william.raillant-clark@mcgill.ca
514-398-2189
McGill University
Source:Eurekalert

Related medicine news :

1. Inhibiting fatty acids in immune cells decreases atherosclerosis risk
2. Advance Toward Test for Aggressive Prostate Cancer
3. DASH FOR DAD Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
4. Jim Huber to Serve as National Spokesman for Know Your Score: Fight Prostate Campaign at Myrtle Beach Golf Holiday in August
5. Few differences in outcomes between open and laparoscopic prostate surgery
6. Two Surgical Methods Equally Successful for Prostate Cancer
7. Genetic Mutation Linked to Prostate Cancer in Blacks
8. Statins May Benefit Prostate Cancer Patients
9. Demand For Mobile Prostate Cancer Brachytherapy Vendor Programs Continues Into 2010
10. Be a Star Athlete in the Fight Against Prostate Cancer
11. Do men with early prostate cancer commit suicide more frequently?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology: